**S5 Table.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Description/Study** | **Galan et al., 2014** | **Smit et al., 2014** | **Basken et al., 2018** | **This Study** |
| **Sample type** | A375 cells and HEK293 cells | BRAFV600E melanoma cells 04.01, 04.07, 93.03 and 00.08; A375 and HEK293 cells | WM239A metastatic melanoma cells | Human lymph node tissue |
| **Starting amount** | 750 µg | 3 mg | 8 mg | 60 µg |
| **Fractionation method** | SCX | SCX | ERLIC | High pH reversed-phase |
| **Number of fractions** | 6 | 45 | 24 | 7 |
| **Phosphopeptide enrichment method** | TiO2 | Ti4+-IMAC | TiO2 | Fe(III)-NTA-IMAC |
| **Number of biological replicates** | 2 | 3 | 3 | 1 |
| **Quantification method** | SILAC | Label-free | SILAC | N/A |
| **Mass spectrometer** | LTQ-Orbitrap Elite | LTQ-Orbitrap Elite/Velos | Orbitrap Fusion, LTQ-Orbitrap Velos | Q-Exactive HF-X |
| **LC gradient** | 100 min | 180 min | 100 min | 120 min |